Celltrion’s US launch of omalizumab-igec adds an interchangeable biosimilar option for eligible patients with chronic spontaneous urticaria.
News|Articles|March 31, 2025
Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates
Author(s)Emma Andrus, Editor
Exclusive Q1 Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first quarter of 2025.
Advertisement
Advertisement
The first quarter of 2025 saw significant developments in the dermatology specialty, with key decisions from the US FDA and a flurry of submissions, trial advancements, and regulatory actions from various organizations driving the pipeline forward.
Related to this article
New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Explore dermatology conferences and meetings taking place this October, including clinical updates, skin of color education, and pediatric dermatology research.
Advertisement
Advertisement